Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Action inhibitors, enhancers |
Mechanism NTRK inhibitors(Neurotrophic tyrosine kinase receptor inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H19F2N5O |
InChIKeyZHJVVJVGTOZLTH-SCADIAGYSA-N |
CAS Registry2209122-25-6 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Nerve Degeneration | Phase 1 | - | 01 Aug 2022 |





